Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of buccal midazolam in pediatric convulsive status epilepticus
2021-002051-10Phase 3
- Sponsor
- Takeda
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Buccolam in status epilepticus (SE), sponsored by Takeda. Primary endpoint: Primary efficacy endpoint.
02
Drugs
Buccolam
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on 2021-002051-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002051-10.